Filed Pursuant to Rule 433 
Registration No. 333-213265-01
STEP Income Securities®  Linked to the Common Stock of Amgen Inc.
BofA Finance LLC (“BofA Finance”)
Bank of America Corporation (“BAC”)
Principal Amount
$10.00 per unit
Approximately one year and one week
Underlying Stock:
Common Stock of Amgen Inc. ( Nasdaq symbol: “AMGN”)
8% per year, paid quarterly
Payout Profile at Maturity
A payment of [$0.10 to $0.50] per unit if the Underlying Stock increases to or above 108% of the Starting Value
1-to-1 downside exposure to decreases in the Underlying Stock, with up to 100% of your principal at risk
Step Level
108% of the Starting Value of the Starting Value
Step Payment
[$0.10 to $0.50] per unit[1% to 5%return over the principal amount, to be determined on the pricing date
Threshold Value
100% of the Starting Value
Preliminary Offering Documents
Exchange Listing
You should read the relevant Preliminary Offering Documents before you invest. 
Click on the Preliminary Offering Documents hyperlink above or call your Financial Advisor for a hard copy.
Risk Factors
Please see the Preliminary Offering Documents for a description of certain risks related to this investment, including, but not limited to, the following:
Depending on the performance of the Underlying Stock as measured shortly before the maturity date, your investment may result in a loss; there is no guaranteed return of principal.
Payments on the notes are subject to the credit risk of BofA Finance and the credit risk of BAC, and actual or perceived changes in the creditworthiness of BofA Finance and BAC are expected to affect the value of the notes. If BofA Finance and BAC become insolvent or are unable to pay their respective obligations, you may lose your entire investment.
Your investment return, if any, is limited to the return represented by the periodic interest payments over the term of the notes and the Step Payment, if any, and may be less than a comparable investment directly in the Underlying Stock.
The initial estimated value of the notes on the pricing date will be less than their public offering price.
If you attempt to sell the notes prior to maturity, their market value may be lower than both the public offering price and the initial estimated value of the notes on the pricing date.
You will have no rights of a holder of the Underlying Stock, and you will not be entitled to receive any shares of the Underlying Stock or dividends or other distributions by the issuer of the Underlying Stock.
The issuer, MLPF&S and their respective affiliates do not control the Underlying Company and are not responsible for any disclosure made by the Underlying Company.  The Underlying Company will have no obligations relating to the notes.
The Redemption Amount will not be adjusted for all corporate events that could affect the Underlying Stock.
BofA Finance LLC (BofA Finance) and Bank of America Corporation (BAC) have filed a registration statement (which includes a prospectus) with the Securities and Exchange Commission (SEC) for the notes that are described in this Guidebook. Before you invest, you should carefully read the prospectus in that registration statement and other documents that BofA Finance and BAC have filed with the SEC for more complete information about BofA Finance, BAC and any offering described in this Guidebook. You may obtain these documents without cost by visiting EDGAR on the SEC website at BofA Finance's Central Index Key, or ClK, on the SEC website is 1682472 and BAC’s CIK on the SEC website is 70858. Alternatively, Merrill Lynch will arrange to send you the prospectus and other documents relating to any offering described in this document if you so request by calling toll-free 1-800-294-1322. BofA Finance and BAC face risks that are specific to their respective businesses, and we encourage you to carefully consider these risks before making an investment in their respective securities.
Final terms will be set on the pricing date within the given range for the specified Market-Linked Investment. Please see the Preliminary Offering Documents
for complete product disclosure, including related risks and tax disclosure.